Prohibition Partners
Home / Reports & Data / The European Cannabis Report: 9th Edition
ReportEurope

The European Cannabis Report: 9th Edition

The 9th Edition of the longest-standing annual report dedicated to Europe's evolving and dynamic legal cannabis market is now available for pre-order.

  • Analyst-written market analysis
  • PDF + data
  • Published 2024

Cited in boardrooms, legal proceedings & government briefings since 2017. Our figures are built to be defended — sourced, modelled and signed off by PP’s analysts.

Trusted by teams at

DIAGEOKPMGBarclaysNovartisBloomberg

About this edition

The 9th Edition of the longest-standing annual report dedicated to Europe's evolving and dynamic legal cannabis market is now available for pre-order. It combines PP’s proprietary market sizing with regulatory analysis, giving investors and corporates a single, citable reference — delivered digitally, licensed for internal use, and backed by the analysts who built the numbers.

PDF + data

delivery format

2024

published

Inside this edition

Overview

Medical The medical cannabis industry in Europe is experiencing significant growth both in regulations and market expansion. The UK leads this growth, surpassing sales expectations due to high per-patient consumption. Germany is poised for substantial growth as a new law simplifies prescription and distribution processes. Regulatory strides across Europe include France's decision to integrate cannabis treatment into mainstream medical care by early 2025, Ukraine's legalisation of medical cannabis in February 2024, Greece treating its first patients, Portugal approving three new products, and Spain initiating public consultations for a medical cannabis framework. Despite slow progress in adult-use cannabis legislation, optimism remains high for medical cannabis in Europe. Adult-Use In 2024, adult-use cannabis has seen notable advancements in Europe's legal landscape. Malta marked its initial sales through non-profit cannabis associations, Germany legalised possession and home cultivation while also allowing cannabis associations, Switzerland expanded adult-use pilot studies, and the Netherlands initiated its controlled supply chain experiment, introducing regulated cannabis to coffeeshops. These milestones signify substantial progress and a shifting attitude towards cannabis among the public, authorities, and governments in Europe.

Contents26
  • Contents
  • Executive Summary
  • Medical Cannabis
  • European Medical Cannabis at a Glance
  • EU-Wide Medical Cannabis Initiative
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Greece
  • Ukraine
  • Financial and Business Overview
  • Adult-Use Cannabis
  • Germany
  • Switzerland
  • Netherlands
  • Malta
  • CBD
  • Novel Foods - EU and UK
  • Legal Status of CBD
  • HHC
  • Market Sizing Analysis
  • Medical Market
  • Adult-Use Market
  • CBD

Who it’s for

Investors & analysts

Defensible sizing and forecasts to underwrite the thesis.

Corporate strategy & FMCG

Opportunity sizing and entry routes across key markets.

More from the library

All research